Back to company

EvodiaBio ApS: Financial statements 2024

CVR: 42569283

EvodiaBio ApS (CVR 42569283) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK -10,008,821 and a net result of DKK -21,106,598 compared with DKK -14,056,555 the year before. Equity amounted to DKK 52,423,684. The solvency ratio was 95.2%. The company had 17 employees in the financial year.

Gross Profit
-10,008,821 kr.
Profit/Loss
-21,106,598 kr.
Equity
52,423,684 kr.
Total Assets
55,043,059 kr.
Employees
17

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2024--10 mio.-21.1 mio.52.4 mio.17
2023--9.9 mio.-14.1 mio.23.6 mio.10
2022--2.9 mio.-6.3 mio.37.7 mio.7

Official annual report

View the official annual report directly on the page with a Pro subscription.

How creditworthy is EvodiaBio ApS?

See the CDS score and get a full credit report with recommended credit limit and payment terms.

Read about the CDS score

Events in 2024

EvodiaBio ApS: The 2023 annual report is outMay 23, 2024

EvodiaBio ApS has published its annual report for 2023. Gross profit came to DKK -9,941,780, and the net result was DKK -14,056,555.

Johan Bitsch Nielsen joins the board of EvodiaBio ApSMay 17, 2024

As of May 17, 2024, Johan Bitsch Nielsen has joined the board of directors of EvodiaBio ApS.

Bart Van Hooland leaves the board of EvodiaBio ApSMay 17, 2024

As of May 17, 2024, Bart Van Hooland has left the board of directors of EvodiaBio ApS.

BII Holdings A/S registered as owner of EvodiaBio ApSMay 17, 2024

As of May 17, 2024, BII Holdings A/S is registered as an owner of EvodiaBio ApS with an ownership share of 5%.

Registered as owner of EvodiaBio ApSMay 17, 2024

As of May 17, 2024, is registered as an owner of EvodiaBio ApS with an ownership share of 5%.

About EvodiaBio ApS

EvodiaBio ApS is a Danish company of the type Anpartsselskab based in Rødovre, founded in 2021. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Camilla Benedicte Kloss Fenneberg. The company's owners include Jarne Elleholm, BII Holdings A/S and FormanBiotech Holding ApS. In 2025, the company reported a gross profit of DKK -8,437,110 and a net result of DKK -26,798,122 compared with DKK -21,106,598 the year before. Equity amounted to DKK 68,626,121.

Other financial years